Thromboembolic Risk in ITP
To view the Prescribing Information and Adverse Event Reporting Information, please click the links below:
Gamunex® (Human normal immunoglobulin) 100 g/L, solution for infusion – click here
Flebogamma DIF® (Human normal immunoglobulin) 50 g/L, solution for infusion – click here
Yimmugo®▼
(Human normal immunoglobulin) 100 g/L, solution for infusion – click here
Intratect® (Human normal immunoglobulin) 100 g/L, solution for infusion – click here
Intratect® (Human normal immunoglobulin) 50 g/L, solution for infusion – click here
Tavlesse® (fostamatinib) 100-mg film-coated tablets – click here
Tavlesse® (fostamatinib) 150-mg film-coated tablets – click here
Tavlesse® is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments underneath the 150mg Tavlesse PI
UK-TVLS-2600008 | Date of Preparation: June 2026